Bactiguard enters development partnership in the dental field

Report this content

Bactiguard today entered an agreement to initiate a global development partnership with Dentsply Sirona in the dental field, a new application area for the Bactiguard technology.

The initial development phase, which is expected to last approximately one year, can generate USD 0.9 million in development and milestone related revenues for Bactiguard. Thereafter, the partnership can evolve into a license agreement, with conditional milestone-related payments of USD1.1 million linked to regulatory approvals. In line with Bactiguard's current licensing agreements, the agreement with Dentsply Sirona would also generate royalties on sales revenue following commercialization.

"We are very excited and proud of the collaboration with a champion in the dental field. About a month ago we expanded our license partnership in orthopedics and we are already entering the dental field, another of our six focus areas", says Anders Göransson, CEO.

"The new deal is a gateway to the growing dental market, and we are confident that Bactiguard's unique technology will create great added value. Given that the dental market is of great strategic interest to us, we already have other types of products in the pipeline that will contribute to increased patient safety and better infection prevention", says Carl Johan Fredin, Chief Licensing Officer.

The development agreement initially addresses a segment of the dental treatment market that according to Clarivate, Millennium Research Group inc was valued at 1.2 billion USD in 2020.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2022-04-08, at 15.58.

For more information, please contact:
Carl Johan Fredin, Chief Licensing Office, phone +46 73 525 72 26

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard